Search results for the GEO ID: GSE37168
(Click on the check boxes provided under "Select for analysis", to initiate grouping)
(Once the selection is made, click on "Add groups" in "Make groups for comparison", to make a group. Scroll down)
GSM ID
GPL ID
Select for analysis
Title
Source name
Description
Characteristics
GSM912717
GPL570
P88-sample1 before treatment progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood time point: before treatment disease progression: progressor individual: P88 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912718
GPL570
P88-sample2 at relapse progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): FCR, Cam+R time point: at relapse disease progression: progressor individual: P88 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912719
GPL570
P14-sample1 before treatment progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood time point: before treatment disease progression: progressor individual: P14 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912720
GPL570
P14-sample2 at relapse progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): FR time point: at relapse disease progression: progressor individual: P14 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912721
GPL570
P14-sample2(dup) at relapse progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): FR time point: at relapse disease progression: progressor individual: P14 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912722
GPL570
P39-sample1 before treatment progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood time point: before treatment disease progression: progressor individual: P39 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912723
GPL570
P39-sample2 at relapse progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): FR time point: at relapse disease progression: progressor individual: P39 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912724
GPL570
P40-sample1 before treatment progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood time point: before treatment disease progression: progressor individual: P40 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912725
GPL570
P40-sample2 at relapse progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): FCR, Cam+R time point: at relapse disease progression: progressor individual: P40 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912726
GPL570
P65-sample1 before treatment progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood time point: before treatment disease progression: progressor individual: P65 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912727
GPL570
P65-sample2 at relapse progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): Cam+R time point: at relapse disease progression: progressor individual: P65 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912728
GPL570
P65-sample2(dup) at relapse progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): Cam+R time point: at relapse disease progression: progressor individual: P65 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912729
GPL570
P66-sample1 before treatment progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood time point: before treatment disease progression: progressor individual: P66 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912730
GPL570
P66-sample2 at relapse progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): FR, Chlor. time point: at relapse disease progression: progressor individual: P66 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912732
GPL570
P66-sample2(dup2) at relapse progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): FR, Chlor. time point: at relapse disease progression: progressor individual: P66 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912733
GPL570
P20-sample1 before treatment progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood time point: before treatment disease progression: progressor individual: P20 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912734
GPL570
P20-sample2 at relapse progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): FR, Cam+R time point: at relapse disease progression: progressor individual: P20 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912735
GPL570
P6-sample1 before treatment progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood time point: before treatment disease progression: progressor individual: P6 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912736
GPL570
P6-sample2 at relapse progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): FR, Chlor. time point: at relapse disease progression: progressor individual: P6 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912737
GPL570
P95-sample1 before treatment progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood time point: before treatment disease progression: progressor individual: P95 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912738
GPL570
P95-sample2 at relapse progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): FR time point: at relapse disease progression: progressor individual: P95 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912739
GPL570
P93-sample1 before treatment progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood time point: before treatment disease progression: progressor individual: P93 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912740
GPL570
P93-sample2 at relapse progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): FR time point: at relapse disease progression: progressor individual: P93 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912741
GPL570
P94-sample1 before treatment progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood time point: before treatment disease progression: progressor individual: P94 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912742
GPL570
P94-sample2 at relapse progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): FR time point: at relapse disease progression: progressor individual: P94 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912743
GPL570
P30-sample1 longitudinal time 1 non-progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): None time point: longitudinal time 1 disease progression: non-progressor individual: P30 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912744
GPL570
P30-sample2 longitudinal time 2 non-progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): None time point: longitudinal time 2 disease progression: non-progressor individual: P30 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912745
GPL570
P19-sample1 longitudinal time 1 non-progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): None time point: longitudinal time 1 disease progression: non-progressor individual: P19 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912746
GPL570
P19-sample2 longitudinal time 2 non-progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): None time point: longitudinal time 2 disease progression: non-progressor individual: P19 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912747
GPL570
P82-sample1 longitudinal time 1 non-progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): None time point: longitudinal time 1 disease progression: non-progressor individual: P82 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912748
GPL570
P82-sample2 longitudinal time 2 non-progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): None time point: longitudinal time 2 disease progression: non-progressor individual: P82 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912749
GPL570
P71-sample1 longitudinal time 1 non-progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): None time point: longitudinal time 1 disease progression: non-progressor individual: P71 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912750
GPL570
P71-sample2 longitudinal time 2 non-progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): None time point: longitudinal time 2 disease progression: non-progressor individual: P71 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912751
GPL570
P11-sample1 before treatment progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood time point: before treatment disease progression: progressor individual: P11 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912752
GPL570
P11-sample2 at relapse progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): FCR time point: at relapse disease progression: progressor individual: P11 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912753
GPL570
P92-sample1 before treatment progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood time point: before treatment disease progression: progressor individual: P92 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912754
GPL570
P92-sample2 at relapse progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): FCR time point: at relapse disease progression: progressor individual: P92 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912755
GPL570
P18-sample2 longitudinal time 2 non-progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): None time point: longitudinal time 2 disease progression: non-progressor individual: P18 Sequential sampling of CLL cells Gene expression data from CLL tumors
GSM912756
GPL570
P18-sample1 longitudinal time 1 non-progressor leukemia cells disease state: chronic lymphocytic leukemia tissue: blood intervening therapy (f- fludarabine, c-cyclophosphamide, r- rituximab, cam. -campath/alemtuzumab, chlor. - chlorambucil): None time point: longitudinal time 1 disease progression: non-progressor individual: P18 Sequential sampling of CLL cells Gene expression data from CLL tumors
 
 
Make groups for comparisons
(2 groups will be compared at a time)
Select GSMs and click on "Add groups"
Enter the group name here:


Select expression type
Transcripts profile based on;
A. Differential status (Up/Down regulation)
B. Absolute calls (Transcribed/Not-detected)
 
Filter results by number of probes